Cargando…
Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway blockade is a promising new cancer therapy. Although PD-1/PD-L1 treatment has yielded clinical benefits in several types of cancer, further studies are required to clarify predictive biomarkers for drug efficacy and...
Autores principales: | Kim, Dong Ha, Kim, HyeongRyul, Choi, Yun Jung, Kim, Seon Ye, Lee, Jung-Eun, Sung, Ki Jung, Sung, Young Hoon, Pack, Chan-Gi, Jung, Min-kyo, Han, Buhm, Kim, Kunhee, Kim, Woo Sung, Nam, Soo Jeong, Choi, Chang-Min, Yun, Miyong, Lee, Jae Cheol, Rho, Jin Kyung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802663/ https://www.ncbi.nlm.nih.gov/pubmed/31399559 http://dx.doi.org/10.1038/s12276-019-0295-2 |
Ejemplares similares
-
Exosomal miR-1260b derived from non-small cell lung cancer promotes tumor metastasis through the inhibition of HIPK2
por: Kim, Dong Ha, et al.
Publicado: (2021) -
Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR‐mutant lung cancer
por: Kim, Dong Ha, et al.
Publicado: (2018) -
Identification of exosomal microRNA panel as diagnostic and prognostic biomarker for small cell lung cancer
por: Kim, Dong Ha, et al.
Publicado: (2023) -
Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement
por: Choi, Se Hoon, et al.
Publicado: (2017) -
Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
por: Park, Ji Hyun, et al.
Publicado: (2016)